1 Ott, P. A., Hodi, F. S. & Robert, C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19, 5300-5309, doi:10.1158/1078-0432.CCR-13- 0143 (2013).
2 Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487-502. e415 (2017).
3 Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61, doi:10.1126/science.aaa8172 (2015).
4 Chmielewski, M. & Abken, H. TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation. ADVANCES IN CELL AND GENE THERAPY 3, e84 (2020).
5 The double edge of cancer immunotherapy. Nature Medicine 23, 137-137, doi:10.1038/nm.4286 (2017).
6 Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17, 2105-2116, doi:10.1200/JCO.1999.17.7.2105 (1999).
7 Jiang, T., Zhou, C. & Ren, S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 5, e1163462, doi:10.1080/2162402X.2016.1163462 (2016).
8 Klapper, J. A. et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113, 293-301, doi:10.1002/cncr.23552 (2008).
9 Alsaab, H. O. et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front Pharmacol 8, 561, doi:10.3389/fphar.2017.00561 (2017).
10 Moynihan, K. D. et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22, 1402-1410, doi:10.1038/nm.4200 (2016).
11 Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363, 711-723, doi:10.1056/NEJMoa1003466 (2010).
12 Ferrari, M., Onuoha, S. C. & Pitzalis, C. Going with the flow: harnessing the power of the vasculature for targeted therapy in rheumatoid arthritis. Drug Discov Today 21, 172-179, doi:10.1016/j.drudis.2015.10.014 (2016).
13 Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 23-34 (2015).
14 Patel, S. P. & Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14, 847-856, doi:10.1158/1535- 7163.MCT-14-0983 (2015).
15 Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13, 473-486, doi:10.1038/nrclinonc.2016.58 (2016).
16 Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378, 158-168, doi:10.1056/NEJMra1703481 (2018).
17 June, C. H., Warshauer, J. T. & Bluestone, J. A. Is autoimmunity the Achilles' heel of cancer immunotherapy? Nat Med 23, 540-547, doi:10.1038/nm.4321 (2017).
18 Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nature Reviews Drug Discovery 18, 175-196, doi:10.1038/s41573-018-0006-z (2019).
19 Danhier, F., Feron, O. & Preat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148, 135-146, doi:10.1016/j.jconrel.2010.08.027 (2010).
20 Chari, R. V., Miller, M. L. & Widdison, W. C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 53, 3796-3827, doi:10.1002/anie.201307628 (2014).
21 Peters, C. & Brown, S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep 35, e00225, doi:10.1042/BSR20150089 (2015).
22 Lambert, J. M. & Chari, R. V. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 57, 6949-6964, doi:10.1021/jm500766w (2014).
23 Goldberg, M. S. Improving cancer immunotherapy through nanotechnology. Nature Reviews Cancer 19, 587-602, doi:10.1038/s41568-019-0186-9 (2019).
24 Lee, E. S., Na, K. & Bae, Y. H. Polymeric micelle for tumor pH and folate- mediated targeting. J Control Release 91, 103-113 (2003).
25 Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65, 271-284 (2000).
26 Yasunaga, M., Manabe, S., Tarin, D. & Matsumura, Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 22, 1776-1783, doi:10.1021/bc200158j (2011).
27 Chen, P., Cescon, M. & Bonaldo, P. Collagen VI in cancer and its biological mechanisms. Trends Mol Med 19, 410-417, doi:10.1016/j.molmed.2013.04.001 (2013).
28 Liang, H. et al. A collagen-binding EGFR antibody fragment targeting tumors with a collagen-rich extracellular matrix. Sci Rep 6, 18205, doi:10.1038/srep18205 (2016).
29 松村保広. in J-STAGE ファルマシア Vol. 54 (2018).
30 Carnemolla, B. et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99, 1659-1665 (2002).
31 Eigentler, T. K. et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 17, 7732-7742, doi:10.1158/1078-0432.CCR-11-1203 (2011).
32 Rybak, J. N., Roesli, C., Kaspar, M., Villa, A. & Neri, D. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 67, 10948-10957, doi:10.1158/0008-5472.CAN-07-1436 (2007).
33 Steiner, M. & Neri, D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 17, 6406-6416, doi:10.1158/1078-0432.CCR-11-0483 (2011).
34 Villa, A. et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122, 2405-2413, doi:10.1002/ijc.23408 (2008).
35 Byrne, K. T. & Vonderheide, R. H. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep 15, 2719-2732, doi:10.1016/j.celrep.2016.05.058 (2016).
36 Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 19, 1035-1043, doi:10.1158/1078-0432.CCR-12- 2064 (2013).
37 Fransen, M. F., Sluijter, M., Morreau, H., Arens, R. & Melief, C. J. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 17, 2270-2280, doi:10.1158/1078-0432.CCR-10-2888 (2011).
38 White, A. L. et al. Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. The Journal of Immunology 187, 1754-1763 (2011).
39 Jackaman, C., Cornwall, S., Graham, P. T. & Nelson, D. J. CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol 89, 255-267, doi:10.1038/icb.2010.88 (2011).
40 Lum, H. D. et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol 79, 1181-1192, doi:10.1189/jlb.0405191 (2006).
41 Rakhmilevich, A. L., Alderson, K. L. & Sondel, P. M. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol 31, 267-278, doi:10.3109/08830185.2012.698337 (2012).
42 Rakhmilevich, A. L., Buhtoiarov, I. N., Malkovsky, M. & Sondel, P. M. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol Immunother 57, 1151-1160, doi:10.1007/s00262-007-0447-4 (2008).
43 Hassan, S. B., Sorensen, J. F., Olsen, B. N. & Pedersen, A. E. Anti-CD40- mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 36, 96-104, doi:10.3109/08923973.2014.890626 (2014).
44 Johnson, P. et al. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin Cancer Res 21, 1321- 1328, doi:10.1158/1078-0432.CCR-14-2355 (2015).
45 Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616, doi:10.1126/science.1198443 (2011).
46 Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25, 876-883, doi:10.1200/JCO.2006.08.3311 (2007).
47 Vonderheide, R. H. et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 62, 949-954, doi:10.1007/s00262-013-1427-5 (2013).
48 Marabelle, A., Kohrt, H., Caux, C. & Levy, R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 20, 1747-1756, doi:10.1158/1078-0432.CCR-13-2116 (2014).
49 Mangsbo, S. M. et al. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity. Clin Cancer Res 21, 1115-1126, doi:10.1158/1078-0432.CCR-14-0913 (2015).
50 Rahimian, S. et al. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. Biomaterials 61, 33-40, doi:10.1016/j.biomaterials.2015.04.043 (2015).
51 Sandin, L. C. et al. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res 2, 80-90, doi:10.1158/2326-6066.CIR- 13-0067 (2014).
52 Irenaeus, S. M. M. et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J Cancer 145, 1189-1199, doi:10.1002/ijc.32141 (2019).
53 Fransen, M. F., Ossendorp, F., Arens, R. & Melief, C. J. Local immunomodulation for cancer therapy: Providing treatment where needed. Oncoimmunology 2, e26493, doi:10.4161/onci.26493 (2013).
54 Nerenberg, P. S., Salsas-Escat, R. & Stultz, C. M. Collagen--a necessary accomplice in the metastatic process. Cancer Genomics Proteomics 4, 319- 328 (2007).
55 Martino, M. M., Briquez, P. S., Ranga, A., Lutolf, M. P. & Hubbell, J. A. Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix. Proc Natl Acad Sci U S A 110, 4563-4568, doi:10.1073/pnas.1221602110 (2013).
56 Martino, M. M. et al. Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing. Sci Transl Med 3, 100ra189, doi:10.1126/scitranslmed.3002614 (2011).
57 De Laporte, L., Rice, J. J., Tortelli, F. & Hubbell, J. A. Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PLoS One 8, e62076, doi:10.1371/journal.pone.0062076 (2013).
58 Tortelli, F., Pisano, M., Briquez, P. S., Martino, M. M. & Hubbell, J. A. Fibronectin binding modulates CXCL11 activity and facilitates wound healing. PLoS One 8, e79610, doi:10.1371/journal.pone.0079610 (2013).
59 Martino, M. M. et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 343, 885-888, doi:10.1126/science.1247663 (2014).
60 Gladue, R. P. et al. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID- hu mice. Cancer Immunol Immunother 60, 1009-1017, doi:10.1007/s00262- 011-1014-6 (2011).
61 Ruter, J., Antonia, S. J., Burris, H. A., Huhn, R. D. & Vonderheide, R. H. Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther 10, 983-993, doi:10.4161/cbt.10.10.13251 (2010).
62 Guy, C. T., Cardiff, R. D. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-961 (1992).
63 Farhood, B., Najafi, M. & Mortezaee, K. CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. Journal of Cellular Physiology 234, 8509- 8521 (2019).
64 Byrne, K. T., Leisenring, N. H., Bajor, D. L. & Vonderheide, R. H. CSF-1R- dependent lethal hepatotoxicity when agonistic CD40 antibody is given before but not after chemotherapy. J Immunol 197, 179-187, doi:10.4049/jimmunol.1600146 (2016).
65 Fransen, M. F., van der Sluis, T. C., Ossendorp, F., Arens, R. & Melief, C. J. Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell- dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 19, 5381-5389, doi:10.1158/1078-0432.CCR-12-0781 (2013).
66 Ellmark, P., Mangsbo, S. M., Furebring, C., Norlen, P. & Totterman, T. H. Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother 66, 1-7, doi:10.1007/s00262-016-1909-3 (2017).
67 Kwong, B., Liu, H. & Irvine, D. J. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials 32, 5134-5147, doi:10.1016/j.biomaterials.2011.03.067 (2011).
68 Grosso, J. F. & Jure-Kunkel, M. N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun 13, 5 (2013).
69 Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 1, 32-42, doi:10.1158/2326-6066.CIR-13-0013 (2013).
70 Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210, 1695-1710, doi:10.1084/jem.20130579 (2013).
71 Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192, 1027-1034 (2000).
72 Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99, 12293-12297, doi:10.1073/pnas.192461099 (2002).
73 Blank, C., Gajewski, T. F. & Mackensen, A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 54, 307-314, doi:10.1007/s00262-004-0593-x (2005).
74 Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73, 3591-3603, doi:10.1158/0008- 5472.CAN-12-4100 (2013).
75 Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107, 4275-4280, doi:10.1073/pnas.0915174107 (2010).
76 Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562, doi:10.1038/nature13904 (2014).
77 Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. Journal for immunotherapy of cancer 2, 1 (2014).
78 Mellati, M. et al. Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care 38, e137-138, doi:10.2337/dc15-0889 (2015).
79 Aznar, M. A. et al. Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally. The Journal of Immunology 198, 31-39, doi:10.4049/jimmunol.1601145 (2017).
80 Sandin, L. C. et al. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology 3, e27614, doi:10.4161/onci.27614 (2014).
81 Ricard-Blum, S. The collagen family. Cold Spring Harb Perspect Biol 3, a004978, doi:10.1101/cshperspect.a004978 (2011).
82 Dubois, C., Panicot-Dubois, L., Merrill-Skoloff, G., Furie, B. & Furie, B. C. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 107, 3902-3906, doi:10.1182/blood-2005-09-3687 (2006).
83 Bergmeier, W. & Hynes, R. O. Extracellular matrix proteins in hemostasis and thrombosis. Cold Spring Harb Perspect Biol 4, a005132, doi:10.1101/cshperspect.a005132 (2012).
84 Nagy, J., Chang, S., Dvorak, A. & Dvorak, H. Why are tumour blood vessels abnormal and why is it important to know? British journal of cancer 100, 865 (2009).
85 Sabrkhany, S., Griffioen, A. W. & Oude Egbrink, M. G. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 1815, 189-196, doi:10.1016/j.bbcan.2010.12.001 (2011).
86 Shahidi, M. Thrombosis and von Willebrand Factor. Adv Exp Med Biol 906, 285-306, doi:10.1007/5584_2016_122 (2017).
87 Addi, C., Murschel, F. & De Crescenzo, G. Design and use of chimeric proteins containing a collagen-binding domain for wound healing and bone regeneration. Tissue Engineering Part B: Reviews (2016).
88 Ribba, A. S. et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 86, 848-854 (2001).
89 Kufe, D. W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 32, 1073-1081, doi:10.1038/onc.2012.158 (2013).
90 Mach, J.-P. et al. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunology Today 2, 239-249, doi:10.1016/0167- 5699(81)90011-6 (1981).
91 Busek, P., Mateu, R., Zubal, M., Kotackova, L. & Sedo, A. Targeting fibroblast activation protein in cancer - Prospects and caveats. Front Biosci (Landmark Ed) 23, 1933-1968 (2018).
92 Ray, A. et al. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget 7, 64390-64399, doi:10.18632/oncotarget.10453 (2016).
93 Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 36, 847-856, doi:10.1038/nbt.4195 (2018).
94 Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23, 709-717, doi:10.1038/nbt1101 (2005).
95 Kumra, H. & Reinhardt, D. P. Fibronectin-targeted drug delivery in cancer. Adv Drug Deliv Rev 97, 101-110, doi:10.1016/j.addr.2015.11.014 (2016).
96 Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat Biomed Eng 4, 531-543, doi:10.1038/s41551-020-0549-2 (2020).
97 Sasaki, K. et al. Engineered collagen-binding serum albumin as a drug conjugate carrier for cancer therapy. Science Advances 5, eaaw6081, doi:10.1126/sciadv.aaw6081 (2019).
98 Williford, J. M. et al. Recruitment of CD103(+) dendritic cells via tumor- targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy. Sci Adv 5, eaay1357, doi:10.1126/sciadv.aay1357 (2019).
99 Katsumata, K. et al. Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies. Science Advances 5, eaay1971, doi:10.1126/sciadv.aay1971 (2019). 100 The double edge of cancer immunotherapy. Nat Med 23, 137, doi:10.1038/nm.4286 (2017). 101 Lee, S. S., Bindokas, V. P. & Kron, S. J. Multiplex three-dimensional optical mapping of tumor immune microenvironment. Sci Rep 7, 17031, doi:10.1038/s41598-017-16987-x (2017).
論文の公開元へ
